How Real-World Mobility Data Can Improve Pharma R&D Productivity

Productivity in biopharmaceutical R&D is driven by a combination of effectiveness (doing the right things) and efficiency (doing things right). The framework below was recently presented by Roche at the recent Digital Biomarkers conference in Basel, and illustrates a number of levers firms can use to improve productivity.

We have used it to show how real-world mobility data can improve R&D productivity in multiple ways, namely enhancing asset value, increasing success rates, reducing trial costs and accelerating cycle times.

Author illustration based on a framework used by Roche

1. Asset Value: Enhancing Clinical Relevance

Enoda’s mobility data reveals how patients function in the real world — beyond what’s visible in clinical settings. This enables pharma teams to:

• Develop more differentiated products based on real-life patient benefit.

• Support label-enabling evidence with concrete functional outcomes.

• Prioritize compounds that show measurable improvement in patient mobility, increasing perceived asset value by payers and regulators.

2. Success Rate: Evidence on a Meaningful Aspect of Health

Mobility (defined as the ability to move freely and easily) is an aspect of health that patients care about deeply. Measuring it in the real world provides:

• concrete evidence of efficacy on this vital aspect of health.

• sensitive data that can clearly demonstrate treatment effects.

3. Costs: Reducing Waste and Improving Trial Design

High-resolution mobility insights enable early detection of efficacy signals, allowing teams to:

• De-risk and speed up go/no-go decisions by grounding them in objective, patient-centric data.

• Detect subtle changes that standard endpoints may miss, improving the odds of clinical success.

• Reduce sample size requirements.

• Minimise protocol amendments and related costs.

4. Cycle Times: Accelerating Evidence Generation

Real-world mobility data is continuous, objective, and remote — enabling:

• Faster interim analyses

• Real-time decision-making in adaptive trial designs

• Earlier access to evidence that supports accelerated approvals

Conclusion. Real-world mobility data obtained from wearable sensors has the potential to improve pharma productivity by helping reduce costs and cycle times, as well as differentiating therapies by providing accurate data on a meaningful aspect of health.

You can find out more by contacting us at info@enoda-health.com.